Tagged with Life Science

Hong Kong Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He traces the organisation’s evolution from US-based acquisitions to a protein/peptide and circular RNA vaccine platform built in Hong Kong, explains…

Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…

Denmark Making Life Sciences Strategic The super-sized contribution of the life sciences sector to Denmark’s national economy can hardly be overstated. With over 100,000 professionals currently engaged in biotech and pharmaceuticals across the country, Denmark already ranks as one of the European Union member states with the largest proportion of the…

USA Chris Molineaux, CEO of Life Sciences Pennsylvania, highlights Pennsylvania’s emergence as a leading life sciences hub, with 3,000+ companies, top NIH-funded universities, and global partnerships drawing investment. He notes that Pennsylvania’s pharmaceutical heritage and growing cell and gene therapy expertise – in addition to other cutting-edge modalities – offer unique…

Denmark As Denmark prepares to assume the rotating presidency of the Council of the European Union on July 1st of 2025, attention is turning to what this small yet strategically positioned country will bring to the table. Under the slogan ‘A strong Europe in a changing world’, the Danish Ministry of…

Denmark Vanessa Vega Saenz discusses Denmark’s strategic approach to attracting foreign investments in life sciences, highlighting the country’s strengths in clinical trials, production, and health data access. Supported by a robust regulatory framework, strong public-private collaboration, and a clear national vision, Denmark is both a competitive European hub and a trusted…

Denmark As Denmark sets its sights on becoming a global leader in life sciences by 2030, Morten Bødskov, Minister for Industry, Business, and Financial Affairs, outlines the strategic pillars of the country’s Life Science Strategy Toward 2030. With an unwavering commitment to strengthening Denmark’s competitive edge in the face of fierce…

Denmark As Denmark’s life science sector matures into a globally engaged, innovation-led ecosystem, the Danish Life Science Cluster has emerged as a central neutral coordinating force, aligning regional strengths, shaping strategic direction, and enabling collaborative transformation across sectors. In this interview, Director Diana Arsovic Nielsen, CEO of the Cluster, reflects on…

Denmark Anette Steenberg, CEO of Medicon Valley Alliance, discusses how the Danish-Swedish cross-border innovation hub is positioning the region as a global leader in life sciences. The Alliance leverages regional strengths and a “triple helix” model of collaboration between hospitals, private companies, and academia in order to deliver world-class competitive value.…

Denmark Home to a score of pioneering biopharma players, Denmark has recognized its life sciences industry as a cornerstone of the economy. After forming a public-private partnership forum in 2021, the Danish Life Sciences Council (DLSC), the government laid out an ambitious strategy for the sector. The DLSC has now taken…

India KV Subramaniam, president of Reliance Life Sciences, a research-driven medical biotech with a fully integrated value chain that covers everything from research to manufacturing, comments on the firm’s unique positioning and its efforts to diversify its portfolio. Moving beyond plasma proteins and biosimilars, Reliance looks to expand into vaccines and…

Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility.   Johnson & Johnson Innovation…